It is always a crap shoot when a trader trades pharma companies…..EVERY company has the next big drug, EVERY company is about to be swallowed up by Big Pharma for huge multiples, EVERY little pharma company is about to sign a out-licensing deal with Merck, Pfizer or other Big Pharma. Unfortunately, most of those dreams never pan out.
Such is the case with Emisphere Technologies, Inc. (EMIS.OB). They have high hopes for their proprietary Eligen® Technology and are developing oral forms of injectable drugs or poorly absorbed compounds.
However, their “promise” appears to be wearing thin with investors. I got a real kick reading the boards on this one. It seems that management has been promising great things for too long with no results.
This stock is not about fundamentals, or potential or big news. It’s about MOMENTUM. EMIS has got it!
Take a look at the chart
Every meaningful indicator is pointing up…..how long the run will last is unknown.
Momentum play, anyone?
EMIS suffers the disease of many small Pharma companies…..crappy balance sheet, no income and uncertain prospects. They company has postponed the release of their 4th Q numbers so they can complete the audit. I don’t know if I would stick around in the stock to find out how their last Q was.
Resistance is at $1.70, $1.80 and $1.95 with the 50 and 200-day MA’s at around $1.84. Make sure you set your stops tight.
Here is what I am looking at for entry/exit points:
Last Close: $1.59
Buy Opinion: $1.55 – $1.65
Short Term Sell: $1.95 (Watch and see if the MA’s will act as support on the way to $1.95)
Long Term Sell: $2.50+
Good Luck and Great Trading,
Disclosure: No positions
InvestorSoup.com is committed to provide intelligent commentary and solid analysis of small cap stocks, micro-cap stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily on the underserved OTC stocks market, or “penny stock” market, which has traditionally been shunned by Wall Street. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.